Saudi Arabia Contract Manufacturing Organizations Market, By Type (Active Pharmaceutical Ingredients (API) Manufacturing, Finished Dosage Formulation (FDF) Development & Manufacturing, Secondary Packaging), By End User (Big Pharmaceuticals, Small and Mid-Size Pharmaceuticals, Generic Pharmaceutical Companies, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

The Saudi Arabia Contract Manufacturing Organizations market was valued at USD 29.68 Million in 2024 and is expected to reach USD 48.80 Million by 2030 with a CAGR of 8.60%. Contract Manufacturing Organizations (CMOs), often referred to as Contract Development and Manufacturing Organizations (CDMOs), are specialized companies that provide manufacturing and development services to other pharmaceutical, biotechnology, and life sciences companies on a contractual basis. CMOs are integral to the pharmaceutical and biotech industries, helping these companies bring their products to market efficiently and cost-effectively. CMOs are primarily known for their manufacturing services. They have facilities equipped to produce a wide range of pharmaceutical and biopharmaceutical products. This includes active pharmaceutical ingredients (APIs), finished dosage forms (tablets, capsules, injectables, etc.), biologics, vaccines, sterile products, and more. CMOs often offer contract development services, which involve assisting pharmaceutical companies in the development and optimization of drug formulations, manufacturing processes, and analytical methods. This can include product formulation, process design, and scale-up activities. Many CMOs invest in advanced manufacturing technologies and processes. They often collaborate with pharmaceutical companies to innovate in manufacturing and implement cutting-edge techniques and technologies.

The expansion of the pharmaceutical and biotechnology sectors in Saudi Arabia drives the demand for CMO services. The development of new drugs, increased healthcare spending, and rising healthcare needs contribute to market growth. The Saudi Arabian government has introduced various initiatives and policies to diversify the economy and promote the life sciences and healthcare industries. These initiatives provide incentives and support for the pharmaceutical and CMO sectors. A push for self-sufficiency in pharmaceutical manufacturing, including active pharmaceutical ingredients (APIs) and finished dosage forms, encourages investments in local CMO capabilities. CMOs often offer specialized expertise and technologies, including biopharmaceutical manufacturing, sterile product manufacturing, and advanced manufacturing techniques. This attracts pharmaceutical companies seeking specific capabilities. CMOs in Saudi Arabia can serve as a gateway to regional and international markets, enhancing the country's position as a global pharmaceutical manufacturing hub.

Key Market Drivers

Vision 2030 and Government Initiatives

The implementation of Vision 2030, Saudi Arabia’s national development plan, has emerged as a pivotal force behind the expansion of the Contract Manufacturing Organizations (CMO) market. By setting clear strategic objectives aimed at diversifying the economy and building a robust healthcare ecosystem, the government is actively fostering an environment that supports and accelerates the growth of the pharmaceutical manufacturing sector with CMOs playing a central role. At the heart of Vision 2030 lies the goal of reducing reliance on oil revenues and promoting the growth of non-oil sectors. Healthcare and pharmaceuticals have been identified as key pillars in this transformation. To support this, the government has introduced localization policies that require multinational pharmaceutical companies to establish local manufacturing operations or partner with domestic CMOs. These mandates have directly increased demand for contract manufacturing services, particularly among foreign companies that lack local infrastructure but wish to enter or expand within the Saudi market. CMOs are thus positioned as strategic enablers that help companies comply with localization requirements while minimizing capital investment.

The most recent collaboration between the Ministry of Industry and Mineral Resources and the Ministry of Investment marks a significant step forward in Saudi Arabia’s mining sector, following the issuance of exploration licenses for multi-mineral deposits in the Jabal Sayid and Al-Hajjlah regions. These licenses collectively span 4,788 square kilometers, with licensed companies committing to invest approximately SAR 366 million (USD 97.6 million) in exploration activities over the next three years. This strategic investment aims to accelerate geological assessment and resource validation in areas identified as having high mineralization potential. In line with its efforts to unlock economic value from natural resources, Saudi Arabia in 2024 revised its estimate of untapped mineral wealth to USD 2.5 trillion, a substantial increase from the USD 1.3 trillion valuation published in 2016. This upward revision reflects the Kingdom’s enhanced geological data, exploration success, and improved valuation methodologies underscoring mining’s growing role as a cornerstone of national economic diversification under Vision 2030.

A key tenet of Vision 2030 is to build local capabilities across the entire value chain, including drug development, formulation, and production. In response, the Saudi government has: Supported the expansion of pharmaceutical industrial clusters such as those in Sudair, Yanbu, and Jazan, Provided grants and technical support to CMOs upgrading facilities to meet international standards, Promoted technology transfer partnerships that allow domestic CMOs to gain expertise in complex manufacturing processes, such as biologics and injectables. This focus on local capacity-building strengthens the domestic CMO industry, positioning it as a credible and competitive alternative to international manufacturers.

Rising Healthcare Expenditure

The steady increase in healthcare expenditure by the Saudi Arabian government is a critical market driver accelerating the expansion of the Contract Manufacturing Organizations (CMO) sector. This upward trend in spending is not only reshaping the national healthcare landscape but also creating substantial opportunities for pharmaceutical outsourcing and third-party manufacturing. The Ministry of Health (MOH) is moving forward with an ambitious privatization strategy that will see the transfer of operations for 290 public hospitals and 2,300 healthcare centers to the private sector. The objective is to increase private sector participation in healthcare from the current 40% to 65%, positioning private operators as key stakeholders in service delivery and infrastructure management. Saudi Arabia has consistently allocated a significant portion of its national budget to healthcare, with allocations seeing steady increases year-on-year. This financial commitment reflects the government’s intent to: Enhance healthcare infrastructure, expand hospitals, clinics, and medical cities, improve access to pharmaceuticals and advanced medical treatments, promote local manufacturing to reduce dependency on imported medicines. Saudi Arabia is positioning itself to capture a significant share of the Middle East’s US$100 billion medical tourism market, leveraging a targeted, two-pronged strategy to establish itself as a regional healthcare destination of choice. The first pillar of this strategy involves substantial investment in premium healthcare infrastructure aimed at attracting international patients seeking advanced, wellness-focused treatments. A prime example is the development of Clinique La Prairie, a luxury medical wellness resort that combines cutting-edge medical therapies with high-end hospitality signaling the Kingdom’s intent to compete with established global players in the high-value medical tourism segment. As the healthcare system becomes more sophisticated and demand for pharmaceuticals rises, the need for cost-efficient and scalable production solutions has led both public and private stakeholders to rely on CMOs.

According to data from the Ministry of Municipal and Rural Affairs, approximately 82.1% of Saudi Arabia’s population resides in urban areas, with only 17.9% living in rural regions. This urban concentration is driving a surge in demand for pharmaceuticals and medical products, particularly in metropolitan hubs where healthcare infrastructure is expanding rapidly. At the same time, rising awareness and improved access in rural areas are creating new market opportunities for pharmaceutical companies and contract manufacturing organizations (CMOs) to support nationwide distribution strategies and ensure consistent medical supply across diverse geographies. This surge in pharmaceutical demand often outpaces the current in-house production capacity of local manufacturers, creating a strong incentive to outsource to CMOs who can rapidly scale production and deliver high volumes under tight timelines. As healthcare costs continue to rise, both government bodies and private healthcare providers are under pressure to control operational costs while maintaining quality and efficiency. Outsourcing manufacturing to CMOs enables: Reduced capital expenditure on manufacturing facilities and equipment, Minimized risk associated with production scale-up or technology upgrades, Enhanced operational flexibility, allowing pharmaceutical firms to focus on R&D and distribution. CMOs, with their specialized capabilities and economies of scale, offer a cost-effective manufacturing model that supports healthcare sustainability objectives.

Download Free Sample Report

Key Market Challenges

Skilled Workforce

The pharmaceutical and biotechnology manufacturing processes often require specialized knowledge and expertise in areas such as bioprocessing, sterile manufacturing, and advanced pharmaceutical technologies. Finding professionals with this specific skill set can be challenging. The number of professionals with experience in pharmaceutical and biotech manufacturing may be limited in Saudi Arabia. Many individuals with such expertise may need to be recruited from outside the country. The demand for skilled professionals in the pharmaceutical and biotechnology sectors can lead to intense competition for talent. CMOs may need to offer competitive compensation packages and incentives to attract and retain qualified employees. Ensuring compliance with stringent regulatory requirements is essential in pharmaceutical manufacturing. This requires a workforce with a deep understanding of regulatory standards, which may be in short supply. Maintaining high standards of quality control and quality assurance is fundamental in pharmaceutical manufacturing. CMOs need professionals with the skills to implement and manage robust quality systems. The pharmaceutical and biotech industries are constantly evolving with new technologies and regulatory changes. CMOs must invest in ongoing training and development to keep their workforce up to date with the latest industry developments. In some cases, CMOs may need to bring in skilled professionals from other countries to fill gaps in the local talent pool. This can add complexity to the recruitment process and require addressing immigration and work permit issues. Ensuring a pipeline of skilled professionals for the future requires cooperation between CMOs and educational institutions. Collaborative efforts can help develop programs that equip students with the necessary skills.

Price Pressures

The CMO market is highly competitive, with numerous providers vying for contracts. This competition can put downward pressure on prices as CMOs seek to attract and retain clients. Pharmaceutical companies, including those in Saudi Arabia, are under pressure to contain costs to remain competitive and deliver affordable healthcare products. They may negotiate aggressively with CMOs to secure lower manufacturing costs. The pharmaceutical industry demands high-quality standards and strict regulatory compliance. Maintaining quality while managing costs can be a delicate balance for CMOs. CMOs often seek to achieve economies of scale to reduce production costs. However, achieving these efficiencies can take time and investment. The push for greater transparency in pricing, including in drug pricing, can influence contract negotiations and lead to more price pressures. In contract negotiations, pharmaceutical companies with substantial production volumes may have more negotiating power, allowing them to seek favorable terms, including pricing. Pharmaceutical companies may pressure CMOs to optimize supply chains, reduce waste, and enhance efficiency to drive down costs. Fluctuations in the prices of raw materials and other production inputs can impact CMOs' production costs and profitability. Evolving regulatory requirements may necessitate adjustments in manufacturing processes and quality control, potentially increasing costs for CMOs.

Key Market Trends

Increasing Outsourcing

Pharmaceutical companies are increasingly focusing on their core competencies, such as research and development and marketing, while outsourcing manufacturing and production to CMOs. This allows them to allocate more resources to innovation and growth. Outsourcing manufacturing to CMOs can often be more cost-effective than maintaining in-house production facilities. CMOs can achieve economies of scale and operational efficiencies, leading to cost savings for pharmaceutical companies. CMOs often specialize in areas, such as biopharmaceuticals, sterile manufacturing, or complex formulations. Pharmaceutical companies can leverage the specialized expertise of CMOs to meet specific manufacturing requirements. CMOs offer the capacity and scalability that pharmaceutical companies may require. They can adjust production volumes to meet fluctuating demand and scale up manufacturing for product launches and clinical trials. CMOs have experience in navigating complex regulatory requirements. They maintain quality systems and regulatory expertise, ensuring that products are manufactured in compliance with local and international standards. CMOs often have facilities and capabilities to serve international markets. This helps pharmaceutical companies expand their global reach without having to establish manufacturing operations in multiple locations. Outsourcing to CMOs can help pharmaceutical companies mitigate risks associated with production, supply chain disruptions, and regulatory changes. CMOs can often provide redundancy and contingency planning. Pharmaceutical companies can benefit from the flexibility provided by CMOs. They can adapt manufacturing processes, change production volumes, and explore new product lines more easily through outsourcing.

Segmental Insights

Type Insights

Based on the category of Type, Active Pharmaceutical Ingredients (API) Manufacturing segment emerged as the fastest growing segment in the Saudi Arabia Contract Manufacturing Organizations Market in 2024. The production of active pharmaceutical ingredients is a critical component of the pharmaceutical supply chain. The Saudi Arabian pharmaceutical market has a growing demand for APIs to support the manufacturing of various pharmaceutical products, including finished dosage forms such as tablets, capsules, and injectables. The local pharmaceutical industry in Saudi Arabia has been expanding, with a focus on manufacturing finished pharmaceutical products. To meet this demand, CMOs specializing in API manufacturing play a vital role in providing the necessary raw materials. CMOs with expertise in API manufacturing offer customized solutions for pharmaceutical companies, enabling them to source specific APIs tailored to their product requirements. This customization is especially important for pharmaceutical companies that need unique or specialized APIs. API manufacturing is subject to stringent regulatory requirements to ensure quality, safety, and efficacy. CMOs specializing in API production are well-equipped to meet these regulatory standards, which is crucial for pharmaceutical manufacturers in Saudi Arabia. API manufacturing often represents a significant portion of the total cost of pharmaceutical production. CMOs that specialize in API manufacturing can achieve economies of scale, cost-efficiency, and quality control measures, which benefit pharmaceutical manufacturers. Pharmaceutical companies in Saudi Arabia and other regions aim to reduce their dependency on imports for APIs. Investing in domestic API manufacturing capabilities through CMOs enhances the country's pharmaceutical self-sufficiency and reduces reliance on international suppliers. These factors are expected to drive the growth of this segment.

Download Free Sample Report

Regional Insights

Northern & Central emerged as the largest market in the Saudi Arabia Contract Manufacturing Organizations Market in 2024, holding the largest market share in terms of value. The Northern and Central regions of Saudi Arabia, particularly the capital city Riyadh in the Central region, boast well-developed infrastructure and excellent connectivity. This makes them attractive locations for CMOs, as they can efficiently transport materials and products to and from these areas. These regions provide access to critical facilities, including transportation hubs, research institutions, and regulatory agencies, which are vital for the pharmaceutical and biotech industry. Proximity to these resources facilitates efficient operations. Riyadh, in the Central region, is the economic and financial center of Saudi Arabia. It's also home to many corporate headquarters and government offices. This concentration of economic activity creates a favorable environment for CMOs seeking business partnerships and government support. The presence of research and innovation centers, universities, and scientific institutions in these regions promotes collaboration and the development of cutting-edge pharmaceutical products and processes, which can benefit CMOs. Regulatory agencies often have a significant presence in capital cities and major economic centers. Being situated in these regions can help CMOs maintain close regulatory compliance and access timely updates on industry standards. The Northern and Central regions tend to have a relatively higher concentration of a skilled and educated workforce. This is particularly important for the pharmaceutical and biotech industry, which relies on highly specialized professionals.

Recent Developments

• In December 2024- Saudi Arabia is accelerating its push to become a regional powerhouse in pharmaceutical manufacturing, biomanufacturing, and R&D, as it prepares to host the inaugural CPHI Middle East at the Riyadh Front Exhibition & Convention Center from 10–12 December 2024. The event is expected to attract over 30,000 pharmaceutical professionals, industry executives, and global decision-makers, marking a pivotal moment in the Kingdom’s industrial transformation. Industry leaders view the launch of CPHI Middle East in Riyadh as a strategic inflection point, reinforcing efforts to establish a competitive domestic manufacturing base and position Saudi Arabia as a central hub for pharmaceutical innovation and supply within the broader Middle East region.
• In September 2023, Lifera, the biopharmaceutical arm of Saudi Arabia’s Public Investment Fund (PIF), has signed a non-binding term sheet with National Resilience, Inc., a U.S.-based, technology-driven biomanufacturing company, to jointly explore the development of state-of-the-art biopharmaceutical manufacturing capabilities in Riyadh.
• In June 2023, The Public Investment Fund (PIF) has officially launched Lifera, a commercial-scale Contract Development and Manufacturing Organization (CDMO) aimed at strengthening Saudi Arabia’s biopharmaceutical production ecosystem. The initiative is a key step in the Kingdom’s efforts to build sovereign capabilities in advanced drug manufacturing, reduce reliance on imports, and establish a globally competitive biomanufacturing sector.   

Key Market Players

• Saudi Arabian Japanese Pharmaceutical Company (SAJAPHCO)
• AJA Pharmaceutical Industries Company LTD
• Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)
• Jamjoom Pharmaceuticals Co.
• Banjara Holdings
• Batterjee Pharmaceutical

Report Scope:

In this report, the Saudi Arabia Contract Manufacturing Organizations Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Saudi Arabia Contract Manufacturing Organizations Market, By Type:

o   Active Pharmaceutical Ingredients (API) Manufacturing

o   Finished Dosage Formulation (FDF) Development & Manufacturing

o   Secondary Packaging

• Saudi Arabia Contract Manufacturing Organizations Market, By End User:

o   Big Pharmaceuticals

o   Small and Mid-Size Pharmaceuticals

o   Generic Pharmaceutical Companies

o   Others

• Saudi Arabia Contract Manufacturing Organizations Market, By Region:

o   Eastern

o   Western

o   Northern & Central

o   Southern

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Saudi Arabia Contract Manufacturing Organizations Market.

Available Customizations:

 Saudi Arabia Contract Manufacturing Organizations market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).